This suggested a specific immune response against the tumor [44], most likely through the dysregulation of NF-κB as the NF-κB pathway is essential for generating a complete and diverse B cell pool, with different B cell subsets showing varying degrees of dependence on NF-κB signaling for survival and development [45]. The gene discussed is NFKB1; the disease is neoplasm.